Paul Hastings Advised Blackstone Life Sciences in Series B Financing of AvenCell Therapeutics
Paul Hastings LLP advised Blackstone Life Sciences in connection with AvenCell Therapeutics’ $112 million Series B financing led by Novo Holdings. AvenCell Therapeutics is a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies. Blackstone Life Sciences is a founding investor of AvenCell Therapeutics.
Partner Samuel Waxman led the Paul Hastings team, which also included associates Adam Winer and Matthew Schob.
More details on the transaction can be found here.
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.